Predictive Modeling of Immunogenicity to Botulinum Toxin A Treatments for Glabellar Lines
The study underscores the importance of understanding BoNT-A immunogenicity in clinical practice. By identifying the main predictors of NAb development and differentiating the immunogenic potential of BoNT-A products, the research provides insights for clinicians in optimizing treatment strategies. It highlights the need for careful treatment customization to reduce immunogenic risks, advocating for further research into the mechanisms of BoNT-A immunogenicity.
Authors
- Parinitha Rao
- Eqram Rahman (ORCID: https://orcid.org/0000-0002-8443-8338)
- Wolfgang G. Philipp‐Dormston (ORCID: https://orcid.org/0000-0002-2845-654X)
- Jean Carruthers (ORCID: https://orcid.org/0000-0002-3838-6768)
- Richard Webb (ORCID: https://orcid.org/0000-0002-2701-626X)
- Nanze Yu
Institutions
- University of British Columbia (CA)
- Witten/Herdecke University (DE)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- UK Research and Innovation (GB)
- Art Innovation (Netherlands) (NL)
- Aesthetic Surgery Center (US)
Publication Details
- Journal
- Plastic & Reconstructive Surgery
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1097/prs.0000000000011748
- Citations
- 7
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.58